Browse RRAD

Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane
Domain PF00071 Ras family
Function

May play an important role in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca(2+) currents. Regulates voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane (By similarity). Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway. Inhibits phosphorylation and activation of CAMK2D.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0003924 GTPase activity
GO:0005516 calmodulin binding
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RRAD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RRAD and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16982863MelanomaPromote immunityIn the s.c. injected B16h5T4 melanoma model, early local but not systemic i.v. administration of syngeneic h5T4-specific CR T cells significantly increased mice survival. This improvement was further enhanced when combined with immunization with Rad.h5T4, followed by post-CR T cell treatment with BMDC in the active therapy model, possibly through mechanisms of enhancing Ag-specific cellular immune responses
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RRAD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RRAD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3770.573
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0170.989
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.660.456
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0680.938
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3830.797
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6230.758
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3480.581
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2380.814
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4390.69
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3280.841
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.30.9
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3440.186
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RRAD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RRAD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RRAD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RRAD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RRAD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RRAD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RRAD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRRAD
NameRas-related associated with diabetes
Aliases REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD
Chromosomal Location16q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RRAD collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.